Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.
Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, Monestier S, Grob JJ, Scemama U, Jacquier A, Lalevee N, Barraud J, Peyrol M, Laine M, Bonello L, Paganelli F, Cohen A, Barlesi F, Ederhy S, Thuny F. Escudier M, et al. Among authors: malissen n. Circulation. 2017 Nov 21;136(21):2085-2087. doi: 10.1161/CIRCULATIONAHA.117.030571. Circulation. 2017. PMID: 29158217 No abstract available.
A novel anti-CD146 antibody specifically targets cancer cells by internalizing the molecule.
Nollet M, Stalin J, Moyon A, Traboulsi W, Essaadi A, Robert S, Malissen N, Bachelier R, Daniel L, Foucault-Bertaud A, Gaudy-Marqueste C, Lacroix R, Leroyer AS, Guillet B, Bardin N, Dignat-George F, Blot-Chabaud M. Nollet M, et al. Among authors: malissen n. Oncotarget. 2017 Nov 28;8(68):112283-112296. doi: 10.18632/oncotarget.22736. eCollection 2017 Dec 22. Oncotarget. 2017. PMID: 29348825 Free PMC article.
Diabetes and Blood Glucose Disorders Under Anti-PD1.
Magis Q, Gaudy-Marqueste C, Basire A, Loundou A, Malissen N, Troin L, Monestier S, Mallet S, Hesse S, Richard MA, Valéro R, Beliard S, Grob JJ. Magis Q, et al. Among authors: malissen n. J Immunother. 2018 Jun;41(5):232-240. doi: 10.1097/CJI.0000000000000218. J Immunother. 2018. PMID: 29481423
HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.
Malissen N, Macagno N, Granjeaud S, Granier C, Moutardier V, Gaudy-Marqueste C, Habel N, Mandavit M, Guillot B, Pasero C, Tartour E, Ballotti R, Grob JJ, Olive D. Malissen N, et al. Oncoimmunology. 2019 Sep 25;8(12):e1665976. doi: 10.1080/2162402X.2019.1665976. eCollection 2019. Oncoimmunology. 2019. PMID: 31741766 Free PMC article.
34 results